CN102716069A - Injection liquid containing ibuprofen and preparation process of injection liquid - Google Patents
Injection liquid containing ibuprofen and preparation process of injection liquid Download PDFInfo
- Publication number
- CN102716069A CN102716069A CN2012101878423A CN201210187842A CN102716069A CN 102716069 A CN102716069 A CN 102716069A CN 2012101878423 A CN2012101878423 A CN 2012101878423A CN 201210187842 A CN201210187842 A CN 201210187842A CN 102716069 A CN102716069 A CN 102716069A
- Authority
- CN
- China
- Prior art keywords
- ibuprofen
- injection
- content
- smaller
- equal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 229960001680 ibuprofen Drugs 0.000 title claims abstract description 71
- 239000007924 injection Substances 0.000 title claims abstract description 39
- 238000002347 injection Methods 0.000 title claims abstract description 39
- 239000007788 liquid Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 229940090044 injection Drugs 0.000 claims abstract description 34
- 229940088523 ibuprofen injection Drugs 0.000 claims abstract description 24
- 239000004475 Arginine Substances 0.000 claims abstract description 21
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000012535 impurity Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000003708 ampul Substances 0.000 claims description 23
- 239000000047 product Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- 238000007689 inspection Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 235000019260 propionic acid Nutrition 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- KEAGRYYGYWZVPC-UHFFFAOYSA-N 1-[4-(2-methylpropyl)phenyl]ethanone Chemical compound CC(C)CC1=CC=C(C(C)=O)C=C1 KEAGRYYGYWZVPC-UHFFFAOYSA-N 0.000 claims description 4
- FEFPDZIYEWFQFK-UHFFFAOYSA-N 2-(4-butylphenyl)propanoic acid Chemical compound CCCCC1=CC=C(C(C)C(O)=O)C=C1 FEFPDZIYEWFQFK-UHFFFAOYSA-N 0.000 claims description 4
- VGMCZELQCNPMQV-UHFFFAOYSA-N 2-(4-ethylphenyl)propanoic acid Chemical compound CCC1=CC=C(C(C)C(O)=O)C=C1 VGMCZELQCNPMQV-UHFFFAOYSA-N 0.000 claims description 4
- RCINGEKPKJQCMO-UHFFFAOYSA-N 2-[4-(2-methylpropanoyl)phenyl]propanoic acid Chemical compound CC(C)C(=O)C1=CC=C(C(C)C(O)=O)C=C1 RCINGEKPKJQCMO-UHFFFAOYSA-N 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000013505 freshwater Substances 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 238000012805 post-processing Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229960003121 arginine Drugs 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 20
- 238000001990 intravenous administration Methods 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000013078 crystal Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- YSGKLGSKOCLPDX-UHFFFAOYSA-N C(=O)O.C(C(C)C)C1=CC=CC=C1 Chemical compound C(=O)O.C(C(C)C)C1=CC=CC=C1 YSGKLGSKOCLPDX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940083243 caldolor Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940016803 ibuprofen chewable tablet Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007896 modified release capsule Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a proportioning method of ibuprofen injection liquid, a preparation process and relevant substance limitation and belongs to the technical field of medicine. The medical auxiliary materials of the injection liquid are arginine, the injection liquid is prepared by mixing the ibuprofen and arginine according to a mol ratio, the total quantity of relevant substances in the injection liquid is lower than 0.5 percent, and in addition, the content of each kind of impurities is respectively lower than 0.1 percent. The pH value of the injection liquid is controlled in a range that the ibuprofen can be completely dissolved, and the crystal separation phenomenon cannot occur. The content of relevant substances of the injection liquid is strictly controlled in a certain range so that the adverse effect generated on human bodied is avoided to the furthest degree during the intravenous drip on patients, and the safety is higher. The ibuprofen injection liquid provided by the invention has the advantages that the preparation process is simple, the operation is easy, the efficiency is high, and products with stable quality can be prepared.
Description
Technical field
The present invention relates to a kind of matching method, preparation technology and related substance limit thereof of ibuprofen injection, belong to medical technical field.
Background technology
Ibuprofen is one type of nonsteroidal anti-inflammatory drug of having used for many years, is effective PG enzymatic synthesis inhibitor, has antiinflammatory preferably, analgesic and analgesic activity, and it is widely used in the pain that treatment of arthritis and various inflammation cause.Be specially adapted to treat rheumatic arthritis, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and neuritis etc.In addition, it is child's febrifuge of World Health Organization (WHO) and the unique common recommendation of U.S. FDA, is the first-selected febrifuge of child of generally acknowledging.
Ibuprofen goes on the market in Britain early than nineteen sixty-eight, because the antipyretic-antalgic aspect is evident in efficacy, and toxicity is low, is superior to aspirin and acetaminophen, thereby market enlarges rapidly.Since ibuprofen preferably curative effect with have less untoward reaction, in the later stage eighties 20th century, the U.S., Britain ratify to transfer it to OTC medicine in succession.
China began to produce ibuprofen in 1979, domestic existing listing dosage form is: ibuprofen tablet, ibuprofen dispersible tablet, ibuprofen-effervescent sheet, ibuprofen oral disintegrating tablets, ibuprofen soft gelatin capsule, ibuprofen syrup, ibuprofen chewable tablet, brufen soft capsule, ibuprofen modified release capsule and ibuprofen oral administration mixed suspension etc.
The appearance of ibuprofen intravenous fluid, can be can not be oral inpatient remove pain and bring down a fever, have very optimistic market prospect.
Ibuprofen is water-soluble hardly but be soluble in alkaline solution, and promptly dissolubility receives the influence of solution pH value.Describe in the description according to the Caldolor of FDA approval, this product design is 100mg/mL, need be diluted to concentration in use smaller or equal to 4mg/mL intravenous drip again.Its diluent is 5% glucose injection and 0.9% sodium chloride injection; The former pH value is 4.40, and the latter 5.50, all slant acidity; This just need not use under the situation of extra pH regulator agent as far as possible; Remove to control the pH value of injection behind the compatibility through the concentration of alkaline solution, it can be guaranteed in blood of human body is accepted scope, can not cause pH value to exceed after the certain limit ibuprofen simultaneously again and occur separating out phenomenon and influence product quality.
A kind of injection of forming by ibuprofen and arginine that relates among the patent CN01823764.9; This drug regimen composition formula is described as ibuprofen and arginic mol ratio is less than 1:1; But the experiment proof needs to use the pH regulator agent that pH value is controlled at more than 7.4; Be that ibuprofen in the ibuprofen injection dissolves fully, can not separate out.But still having injection stability hidden danger, there is possible potential safety hazard in its related substances meeting overrun even use.
Among the patent CN201010293328.9 prescription of being made up of ibuprofen and cosolvent (arginine) is advised that ibuprofen and arginic mol ratio are 1:1.001-2; This prescription can guarantee that ibuprofen can not separated out under suitable pH value; But must use the pH regulator agent to reduce pH value and accept scope to reach blood of human body; And big as the required quantitative change of the arginine of pharmaceutic adjuvant, cost also uprises thereupon.In addition, the content of related substance inspection is still low inadequately for injection under this pharmaceutical composition proportioning.
Therefore, this area still needs a kind ofly not only to have solved the water miscible problem of ibuprofen, but also can the related substance of injection be reduced to ibuprofen injection prescription and the preparation technology who minimizes and reduce the industry cost.
Summary of the invention
The object of the invention is to remedy the deficiency of above set forth to existing ibuprofen injection and patent thereof, provides a kind of and can significantly improve product quality and stability, higher ibuprofen injection prescription and the preparation technology thereof of safety.Prove that through experimentation the present invention can effectively solve the solubility of ibuprofen, avoid separating out, reducing the content of related substance in the injection, reduce the industry cost.
According to technical scheme provided by the invention, a kind of injection that contains ibuprofen, composition is following: comprise ibuprofen, arginine and injection; Wherein ibuprofen and arginine mol ratio are 1.0:0.9 ~ 1.1; Ibuprofen shared mass/volume percentage ratio in injection is 10%, and arginine shared mass/volume percentage ratio in injection is 7.6% ~ 9.3%; The injection pH value is 7.0 ~ 8.0.
Said ibuprofen and arginine mol ratio are 1:1.
Said arginine shared mass/volume percentage ratio in injection is 8.444%.
A kind of preparation technology who contains the injection of ibuprofen, preparation process is following:
(1) washing of ampoule: get the neutral density glass ampoule, in ampoule, pour into deionized water earlier, 100 ℃ were boiled 25 ~ 35 minutes, and water dumping while hot with fresh water for injection lavation for several times, placed 160 ~ 170 ℃ of baking ovens 2 ~ 4 hours immediately, and taking-up is put cold, subsequent use;
(2) dosing: get arginine 303.99mg ~ 371.55mg earlier, add water for injection 2.4mL ~ 3.6mL that supersound process is crossed, stir and make its dissolving, add the 400.00mg ibuprofen again, the ultrasonic agitation dissolving; Supersonic frequency is 50 ~ 100Hz, and dissolution time is 15 ~ 30 minutes; Using pH regulator agent regulator solution pH value is 7.0 ~ 8.0, and restock water for injection 1.6mL ~ 0.4mL stirs, and adds that to account for total liquor capacity mass ratio be 0 ~ 0.5% needle-use activated carbon again, stirs 20 ~ 40 minutes down in 50 ~ 60 ℃; Utilize defecator and 0.22 ~ 0.45 μ m microporous filter to the clear of filtrating the gained medicinal liquid, get final ibuprofen filtrating;
(3) fill and post processing: final ibuprofen filtrating Chinese medicine content, pH value that determination step (2) obtains, according to calculating the loading amount fill; Being about to final ibuprofen filtrates by the labelled amount fill in 5mL or 10mL ampoule; After the fill with ampoule fusion sealing;
(4) sterilization and quality inspection: with the wet-hot steam sterilization 8min ~ 20min under 96 ~ 121 ℃ of conditions of the ibuprofen injection behind the sealing by fusing in the step (3); To its leak detection, lamp inspection, the packing warehouse-in promptly gets the product ibuprofen injection.
Content of impurities is smaller or equal to 0.5% of gross mass in the said product ibuprofen injection;
Wherein, the content of impurity 4-isobutyl acetophenone is smaller or equal to 0.1%; The benzoic content of impurity 4-isobutyl group is smaller or equal to 0.1%; The content of impurity 2-(3-isobutyl phenenyl) propanoic acid is smaller or equal to 0.1%; The content of impurity 2-(4-butyl phenyl) propanoic acid is smaller or equal to 0.1%; The content of impurity 3-(4-isobutyl phenenyl) propanoic acid is smaller or equal to 0.1%; Impurity 7-(2-aminomethyl phenyl)-1-[4-(2-methyl-propyl) phenyl]-1,2,3,4-tetralin-1, the content of 4-dicarboxylic acids is smaller or equal to 0.1%; The content of impurity 2-(4-isobutyryl phenyl) propanoic acid is smaller or equal to 0.1%; The content of impurity 2-(4-ethylphenyl) propanoic acid is smaller or equal to 0.1%.
All charge into nitrogen protection in the said step (3) before and after the ampoule filling medicinal liquid.
Adopt needle-use activated carbon to filter in the step of preparation process of the present invention and can remove bacterial endotoxin, and guarantee the sample solution clear.Adopt defecator to cooperate the micropore fine straining, can raise the efficiency, guarantee product quality.Can guarantee the aseptic level of product with 0.22 ~ 0.45 μ m microporous filter.Inflated with nitrogen can effectively be removed residual oxygen content in the ampoule before the fill, reduces the probability that related substance produces.
The present invention has following advantage: the present invention is controlled at one with the injection pH value dissolves completely in the scope ibuprofen, crystal promptly can not take place separate out phenomenon.The content of injection related substance is strict controlled in the certain limit, when making it to patient's intravenous drip, as much as possible avoids to property human body is produced untoward reaction, safety is higher.Ibuprofen injection preparation technology described in the present invention is simple, easy to operate, efficient is high, can make stay-in-grade product.
Description of drawings
Fig. 1 is that principal agent ibuprofen and 7 kinds of impurity mix the appearance liquid chromatogram.
Fig. 2 is a 4-isobutyl acetophenone liquid chromatogram.
Fig. 3 is a 4-isobutyl-benzene formic acid liquid chromatogram.
Fig. 4 is 2-(3-isobutyl phenenyl) propanoic acid liquid chromatogram.
Fig. 5 is 2-(4-butyl phenyl) propanoic acid liquid chromatogram.
Fig. 6 is 7-(2-aminomethyl phenyl)-1-[4-(2-methyl-propyl) phenyl]-1,2,3,4-tetralin-1,4-dicarboxylic acids liquid chromatogram.
Fig. 7 is 2-(4-isobutyryl phenyl) propanoic acid liquid chromatogram.
Fig. 8 is 2-(4-ethylphenyl) propanoic acid liquid chromatogram.
Fig. 9 is ibuprofen injection sample (embodiment 1 and a 2) blank solvent liquid chromatogram.
Figure 10 is the ibuprofen injection sample liquid chromatogram of embodiment 1 preparation.
Figure 11 is the ibuprofen injection sample liquid chromatogram of embodiment 2 preparations.
The specific embodiment
Below in conjunction with embodiment the present invention is described in further detail, but be not to be limitation of the present invention, the equal replacement of every any this area of doing according to the disclosure of invention all belongs to protection scope of the present invention.
Embodiment 1
Per 200 ibuprofen injections contain following ingredients: ibuprofen 80.000g (0.388mol); Arginine 67.551g (0.388mol); Water for injection 800mL.
The preparation technology who contains the injection of ibuprofen
(1) washing of ampoule: get neutral density glass ampoule (specification 5mL), with pouring into deionized water in the ampoule earlier, 100 ℃ were boiled 30 minutes, and water dumping while hot with fresh water for injection lavation twice, placed 160 ℃ of baking ovens 2 hours immediately, and taking-up is put cold, subsequent use.
(2) dosing: get the recipe quantity arginine earlier, add supersound process and cross water for injection 700mL, stir and make dissolving; Add the recipe quantity ibuprofen again; The ultrasonic agitation dissolving, surveying pH value is 7.8 ~ 8.0, restock water for injection is to full dose; Stir, add 0.1% (w/v) needle-use activated carbon and stir 30min down for 55 ℃.Earlier medicinal liquid is filtered with buchner funnel, reuse core defecator and 0.22 μ m filtering with microporous membrane take off charcoal, filtrate at last that it is clear and bright to be filtered to filtrating through G4 glass incipient fusion filter, ibuprofen filtrating.
(3) fill and post processing: final ibuprofen filtrating Chinese medicine content, pH value that determination step (2) obtains, according to calculating the loading amount fill; Being about to final ibuprofen filtrates by the labelled amount fill in 5mL or 10mL ampoule; After the fill with ampoule fusion sealing;
(4) sterilization and quality inspection: with the wet-hot steam sterilization 8min ~ 20min under 96 ~ 121 ℃ of conditions of the ibuprofen injection behind the sealing by fusing in the step (3); To its leak detection, lamp inspection, the packing warehouse-in promptly gets the product ibuprofen injection.
Embodiment 2
Per 200 ibuprofen injections contain following ingredients: ibuprofen 160.000g (0.776mol); Arginine 135.108g (0.776mol); Water for injection 1600mL.
The preparation technology who contains the injection of ibuprofen:
(1) washing of ampoule: get neutral density glass ampoule (specification 10mL), with pouring into deionized water in the ampoule earlier, 100 ℃ were boiled 30 minutes, and water dumping while hot with fresh water for injection lavation twice, placed 160 ℃ of baking ovens 2 hours immediately, and taking-up is put cold, subsequent use.
(2) dosing: get the recipe quantity arginine earlier, add supersound process and cross water for injection 1400mL, stir and make dissolving; Add the recipe quantity ibuprofen again, the ultrasonic agitation dissolving, surveying pH value is 7.8 ~ 8.0; Restock water for injection is to full dose; Stir, (w/v, quality: volume) needle-use activated carbon stirs 40min down for 60 ℃ to add 0.2%.Earlier medicinal liquid is filtered with buchner funnel, reuse core defecator and 0.22 μ m filtering with microporous membrane take off charcoal, filtrate at last that it is clear and bright to be filtered to filtrating through G4 glass incipient fusion filter, ibuprofen filtrating.
(3) fill and post processing: final ibuprofen filtrating Chinese medicine content, pH value that determination step (2) obtains, according to calculating the loading amount fill; Being about to final ibuprofen filtrates by the labelled amount fill in 5mL or 10mL ampoule; After the fill with ampoule fusion sealing;
(4) sterilization and quality inspection: with the wet-hot steam sterilization 8min ~ 20min under 96 ~ 121 ℃ of conditions of the ibuprofen injection behind the sealing by fusing in the step (3); To its leak detection, lamp inspection, the packing warehouse-in promptly gets the product ibuprofen injection.
1 pair of related substance standard substance of application implementation example position analysis:
Embodiment 1 is carried out the analysis of related substance with routine 2 ibuprofen injections.
Chromatographic condition
Chromatographic column: Galaksil EF-C 18-H 5um, 4.6 * 150mm
Mobile phase: A: pure water (phosphoric acid adjust pH to 2.5 ~ 3.5): acetonitrile=50 ~ 72:50 ~ 28; B: pure acetonitrile
Adopt gradient elution method, gradient condition is following:
Detect wavelength: 214nm
Flow velocity: 2mL/min
Column temperature: 20 ~ 30 ℃
Sample size: 20 μ L
1, the location of related substance standard substance
The preparation of test liquid: it is an amount of that precision is measured each related substance standard substance respectively, adds mobile phase A and process the solution that every 1mL contains 0.25mg, as need testing solution.By above chromatographic condition sample introduction, all related substances are all accomplished the location, and separating degree is better, and are up to specification, also do not influence the peak that of principal agent ibuprofen, see that Fig. 1 to Fig. 8 and table 1 are to table 8.
Table 1 principal agent ibuprofen and 7 kinds of impurity mix appearance liquid chromatogram test result
Table 2 4-isobutyl acetophenone liquid chromatogram test result.
Table 3 4-isobutyl-benzene formic acid liquid chromatogram test result.
Table 4 2-(3-isobutyl phenenyl) propanoic acid liquid chromatogram test result.
Table 5 2-(4-butyl phenyl) propanoic acid liquid chromatogram test result.
Table 7 2-(4-isobutyryl phenyl) propanoic acid liquid chromatogram test result.
Table 8 2-(4-ethylphenyl) propanoic acid liquid chromatogram test result.
2, the detection of ibuprofen related substance
The preparation of test liquid: it is an amount of with embodiment 2 ibuprofen that precision is measured embodiment 1 respectively, adds mobile phase A and process the solution that every 1mL contains 4mg, as need testing solution.By above chromatographic condition sample introduction, the data result of related substance is respectively 0.067% and 0.083%, sees Figure 10 and Figure 11 and table 10,11.Fig. 9 is ibuprofen injection sample (embodiment 1 and a 2) blank solvent liquid chromatogram.
The ibuprofen injection sample liquid chromatogram test result of table 10 embodiment 1 preparation.
The ibuprofen injection sample liquid chromatogram test result of table 11 embodiment 2 preparations.
Claims (6)
1. an injection that contains ibuprofen is characterized in that composition is following: comprise ibuprofen, arginine and injection; Wherein ibuprofen and arginine mol ratio are 1.0:0.9 ~ 1.1; Ibuprofen shared mass/volume percentage ratio in injection is 10%, and arginine shared mass/volume percentage ratio in injection is 7.6% ~ 9.3%; The injection pH value is 7.0 ~ 8.0.
2. contain the injection of ibuprofen according to claim 1, it is characterized in that: said ibuprofen and arginine mol ratio are 1:1.
3. contain the injection of ibuprofen according to claim 1, it is characterized in that: said arginine shared mass/volume percentage ratio in injection is 8.444%.
4. preparation technology who contains the injection of ibuprofen is characterized in that preparation process is following:
(1) washing of ampoule: get the neutral density glass ampoule, in ampoule, pour into deionized water earlier, 100 ℃ were boiled 25 ~ 35 minutes, and water dumping while hot with fresh water for injection lavation for several times, placed 160 ~ 170 ℃ of baking ovens 2 ~ 4 hours immediately, and taking-up is put cold, subsequent use;
(2) dosing: get arginine 303.99mg ~ 371.55mg earlier, add water for injection 2.4mL ~ 3.6mL that supersound process is crossed, stir and make its dissolving, add the 400.00mg ibuprofen again, the ultrasonic agitation dissolving; Supersonic frequency is 50 ~ 100Hz, and dissolution time is 15 ~ 30 minutes; Using pH regulator agent regulator solution pH value is 7.0 ~ 8.0, and restock water for injection 1.6mL ~ 0.4mL stirs, and adds that to account for total liquor capacity mass ratio be 0 ~ 0.5% needle-use activated carbon again, stirs 20 ~ 40 minutes down in 50 ~ 60 ℃; Utilize defecator and 0.22 ~ 0.45 μ m microporous filter to the clear of filtrating the gained medicinal liquid, get final ibuprofen filtrating;
(3) fill and post processing: final ibuprofen filtrating Chinese medicine content, pH value that determination step (2) obtains, according to calculating the loading amount fill; Being about to final ibuprofen filtrates by the labelled amount fill in 5mL or 10mL ampoule; After the fill with ampoule fusion sealing;
(4) sterilization and quality inspection: with the wet-hot steam sterilization 8min ~ 20min under 96 ~ 121 ℃ of conditions of the ibuprofen injection behind the sealing by fusing in the step (3); To its leak detection, lamp inspection, the packing warehouse-in promptly gets the product ibuprofen injection.
5. contain the injection of ibuprofen according to claim 1, it is characterized in that: content of impurities is smaller or equal to 0.5% of gross mass in the said product ibuprofen injection;
Wherein, the content of impurity 4-isobutyl acetophenone is smaller or equal to 0.1%; The benzoic content of impurity 4-isobutyl group is smaller or equal to 0.1%; The content of impurity 2-(3-isobutyl phenenyl) propanoic acid is smaller or equal to 0.1%; The content of impurity 2-(4-butyl phenyl) propanoic acid is smaller or equal to 0.1%; The content of impurity 3-(4-isobutyl phenenyl) propanoic acid is smaller or equal to 0.1%; Impurity 7-(2-aminomethyl phenyl)-1-[4-(2-methyl-propyl) phenyl]-1,2,3,4-tetralin-1, the content of 4-dicarboxylic acids is smaller or equal to 0.1%; The content of impurity 2-(4-isobutyryl phenyl) propanoic acid is smaller or equal to 0.1%; The content of impurity 2-(4-ethylphenyl) propanoic acid is smaller or equal to 0.1%.
6. like the said preparation technology who contains the injection of ibuprofen of claim 2, it is characterized in that: all charge into nitrogen protection in the said step (3) before and after the ampoule filling medicinal liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101878423A CN102716069A (en) | 2012-06-07 | 2012-06-07 | Injection liquid containing ibuprofen and preparation process of injection liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101878423A CN102716069A (en) | 2012-06-07 | 2012-06-07 | Injection liquid containing ibuprofen and preparation process of injection liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102716069A true CN102716069A (en) | 2012-10-10 |
Family
ID=46942029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101878423A Pending CN102716069A (en) | 2012-06-07 | 2012-06-07 | Injection liquid containing ibuprofen and preparation process of injection liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102716069A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040734A (en) * | 2012-12-20 | 2013-04-17 | 蚌埠丰原涂山制药有限公司 | High-stability ibuprofen injection and preparation method thereof |
| CN108158980A (en) * | 2016-12-07 | 2018-06-15 | 浙江普利药业有限公司 | Arginine Ibuprofen parenteral solution and preparation method thereof |
| CN109521117A (en) * | 2018-12-07 | 2019-03-26 | 成都倍特药业有限公司 | A kind of detection method of the ibuprofen injection in relation to substance |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101966147A (en) * | 2010-09-27 | 2011-02-09 | 四川阳光润禾药业有限公司 | Ibuprofen injection composite and preparation method thereof |
-
2012
- 2012-06-07 CN CN2012101878423A patent/CN102716069A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101966147A (en) * | 2010-09-27 | 2011-02-09 | 四川阳光润禾药业有限公司 | Ibuprofen injection composite and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040734A (en) * | 2012-12-20 | 2013-04-17 | 蚌埠丰原涂山制药有限公司 | High-stability ibuprofen injection and preparation method thereof |
| CN108158980A (en) * | 2016-12-07 | 2018-06-15 | 浙江普利药业有限公司 | Arginine Ibuprofen parenteral solution and preparation method thereof |
| CN109521117A (en) * | 2018-12-07 | 2019-03-26 | 成都倍特药业有限公司 | A kind of detection method of the ibuprofen injection in relation to substance |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104586758B (en) | A kind of paracetamol injection determined and preparation method thereof | |
| CN101966147B (en) | Ibuprofen injection composite and preparation method thereof | |
| CN102716069A (en) | Injection liquid containing ibuprofen and preparation process of injection liquid | |
| CN101455631A (en) | Meglumine cyclic adenosine injection and preparation technique thereof | |
| CN101627967B (en) | Ambroxol hydrochloride liquid preparation and preparation method thereof | |
| CN102836123A (en) | Injection containing levetiracetam active ingredient and technology for preparing injection | |
| CN106963729B (en) | It is a kind of to be used to prevent pharmaceutical preparation of operative hemorrhage and preparation method thereof | |
| CN104784113B (en) | A kind of composition containing Linezolid and preparation method thereof | |
| CN101336903B (en) | Preparation method of (s)-ornidazole disodium phosphate intravenous preparation for injection | |
| CN103371967A (en) | Furosemide injection and preparation process thereof | |
| CN102228428B (en) | Large-volume injection composition containing vinpocetine and preparation method thereof | |
| CN116327697A (en) | A kind of norepinephrine bitartrate injection and its preparation process | |
| CN103070834A (en) | Lyophilized powder containing esomeprazole | |
| CN102552210B (en) | Entecavir capsule and preparation method thereof | |
| CN102824340A (en) | Ibuprofen composition injection and preparation method thereof | |
| CN111166716A (en) | Naproxen injection and preparation method thereof | |
| CN101703466A (en) | Borneol injection and preparation method thereof | |
| CN106474130A (en) | A kind of compound recipe flu oral administration solution and preparation method thereof | |
| CN104146951B (en) | Dexibuprofen injection and preparation method thereof | |
| CN103893767A (en) | Ibuprofen medicine composition with stable quality | |
| CN102552117B (en) | Injection containing ibuprofen and preparation method of injection | |
| CN104000777B (en) | A kind of levofloxacin preparation | |
| CN102138893A (en) | Preparation process and use of sodium lysinrofen chloride injection | |
| CN103505408A (en) | Preparation method of oxiracetam glucose/sodium chloride injection | |
| CN103877015B (en) | A kind of preparation method of Bisolvon glucose injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121010 |